Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 10Phase 1/2 9Phase 2/3 2Phase 1 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 11Esophageal Squamous Cell Carcinoma 8Esophageal Neoplasms 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Nasopharyngeal Carcinoma 6Lung Neoplasms 6Head and Neck Neoplasms 5Gallbladder Neoplasms 5Cholangiocarcinoma 5Pancreatic Neoplasms 4Mesothelioma 4Breast Neoplasms 4Biliary Tract Neoplasms 4Stomach Neoplasms 3Oropharyngeal Neoplasms 3Neoplasm Metastasis 3Carcinoma 3Urinary Bladder Neoplasms 2Osteosarcoma 2Neoplasms 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Bile Duct Neoplasms 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Thymoma 1Thymic epithelial tumor 1Testicular Neoplasms 1

Interventions

Gemcitabine 4Cisplatin 2vinflunine 1valrubicin 1pembrolizumab 1enfortumab vedotin 1cabazitaxel 1XRP6258 1Rogaratinib 1Oncolytic Virotherapy 1Mitomycin 1Interferons 1Drug Therapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Carcinoma, Transitional Cell × Cisplatin × Clear all
NCT07129993 2026-05-14

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Daiichi Sankyo

Phase 2/3 Recruiting
630 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Vasgene Therapeutics, Inc

Phase 2/3 Recruiting
700 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡